Curated News
By: NewsRamp Editorial Staff
November 17, 2026

BioCorRx Advances LUCEMYRA Transition, BICX104 Trial, and Patent Protection

TLDR

  • BioCorRx secured new NDCs for LUCEMYRA and authorized generics, initiated BICX104 Phase 1, and gained patent protection to strengthen market position.
  • BioCorRx established new NDCs under its labeler code, initiated a Phase 1 trial for BICX104, and secured U.S. Patent No. 12,569,430 for a biodegradable naltrexone implant.
  • BioCorRx advances addiction treatment with LUCEMYRA and BICX104, aiming to improve adherence and outcomes for opioid use disorder and save lives.
  • BioCorRx's BICX104 is a biodegradable naltrexone implant designed to provide continuous release over extended periods, potentially overcoming daily adherence challenges.

Impact - Why it Matters

This news matters because it highlights tangible progress in the fight against opioid use disorder, a public health crisis affecting millions. BioCorRx’s commercial transition of LUCEMYRA® ensures continued access to a vital withdrawal management medication, while the Phase 1 study of BICX104—a long-acting implant—could address adherence challenges that plague current therapies. The new patent and leadership additions further solidify the company’s position to deliver innovative treatments, potentially improving outcomes for patients and reducing the societal burden of addiction.

Summary

BioCorRx Inc. (OTC: BICX), together with its pharmaceutical subsidiary BioCorRx Pharmaceuticals Inc., has reported a series of strategic milestones in its third-quarter 2026 financial filing, signaling a transformative year of execution. The company established new National Drug Codes (NDCs) under its own labeler code for all four branded LUCEMYRA® (lofexidine) and Authorized Generic SKUs, positioning itself to complete the commercial transition of the portfolio by year-end while maintaining uninterrupted market supply. LUCEMYRA® is an FDA-approved medication indicated to mitigate opioid withdrawal symptoms in adults.

In clinical development, BioCorRx initiated and progressed a Phase 1 study of BICX104, an investigational biodegradable naltrexone implant, under the FDA’s 505(b)(2) pathway with support from the National Institute on Drug Abuse (NIDA). The study, detailed on ClinicalTrials.gov Identifier: NCT07269873, evaluates BICX104 with or without bupropion compared to Vivitrol®. The company also secured U.S. Patent No. 12,569,430 for a “Biodegradable Implant Including Naltrexone,” expanding its intellectual property protection. Additionally, BioCorRx strengthened its leadership with the appointment of Louis Lucido as Chair of the Board and former Acting White House Drug Policy Director Richard J. Baum to its Strategic Advisory Board.

CEO Lourdes Felix emphasized that these achievements build real momentum heading into 2027. BioCorRx Inc. offers the Beat Addiction Recovery program and the UnCraveRx® Weight Loss Program, while its subsidiary focuses on commercializing LUCEMYRA® and developing BICX104 for opioid use disorder (OUD) and alcohol use disorder. With approximately 4.0 million people in the U.S. estimated to have OUD and only 15.7% receiving medication treatment, the company’s efforts address a significant unmet need. For more information, visit www.BioCorRx.com.

Source Statement

This curated news summary relied on content distributed by NewMediaWire. Read the original source here, BioCorRx Advances LUCEMYRA Transition, BICX104 Trial, and Patent Protection

Blockchain registration record for this content